Compare LSTR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTR | GKOS |
|---|---|---|
| Founded | 1991 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.3B |
| IPO Year | 1993 | 2015 |
| Metric | LSTR | GKOS |
|---|---|---|
| Price | $142.36 | $109.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $153.17 | $132.00 |
| AVG Volume (30 Days) | 662.8K | ★ 829.6K |
| Earning Date | 01-28-2026 | 02-17-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | ★ $4,757,445,000.00 | $469,820,000.00 |
| Revenue This Year | $6.74 | $33.04 |
| Revenue Next Year | $9.08 | $22.62 |
| P/E Ratio | $42.97 | ★ N/A |
| Revenue Growth | N/A | ★ 30.38 |
| 52 Week Low | $119.32 | $73.16 |
| 52 Week High | $165.25 | $161.78 |
| Indicator | LSTR | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 42.52 |
| Support Level | $129.77 | $105.37 |
| Resistance Level | $165.25 | $115.19 |
| Average True Range (ATR) | 6.93 | 5.08 |
| MACD | -1.98 | -1.55 |
| Stochastic Oscillator | 35.48 | 17.47 |
Landstar System is an agent based asset-light third-party logistics provider focused on domestic truck brokerage. Historically, around half of its truck transportation freight is hauled by leased owner-operators with the remainder hauled by third-party broker-carriers. To a smaller degree, it offers intermodal, global air and ocean forwarding, and warehousing services. Landstar also runs a small business that offers insurance programs to captive owner-operators. It has a long history of industry-leading execution and operating profitability.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.